Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Read More →
Olaparib 150 mg
Olaparib is a targeted anticancer medicine belonging to a class of medicines known as poly (ADP-ribose) polymerase (PARP) inhibitors. It is designed to interfere with certain DNA-repair processes that cancer cells may depend on for survival. Olaparib is used in specific cancer treatment settings, particularly when tumors have certain genetic or molecular characteristics such as BRCA1 or BRCA2 mutations or, for some indications, evidence of homologous recombination deficiency (HRD).
The well-established reference product containing olaparib is Lynparza. Regulatory information from the U.S. Food and Drug Administration and the European Medicines Agency provides the principal reference for understanding olaparib’s approved uses, dosing principles, safety profile, and clinical role.
Olanib 150 mg – Everest Pharmaceuticals Ltd.
Generic Name: Olaparib
Strength: 150 mg
Company: Everest Pharmaceuticals Ltd.
Olanib 150 is listed by Everest Pharmaceuticals Ltd. as an olaparib product containing 150 mg of olaparib. The manufacturer’s product catalogue places Olanib among its pharmaceutical products.
The appropriate use of Olanib depends on the approved indication applicable to the patient and the prescribing information associated with the product.
Olakin 150 mg – Ziska Pharmaceuticals Ltd.
Generic Name: Olaparib
Strength: 150 mg
Company: Ziska Pharmaceuticals Ltd.
Olakin 150 is listed in Ziska Pharmaceuticals Ltd. oncology portfolio as an olaparib product.
As with any prescription anticancer medicine, patients should confirm the product identity, strength, manufacturer information, packaging, and applicable prescription requirements before use.
Available Olaparib 150 mg Products
The products specifically identified for this website are:
| Generic Medicine | Brand | Strength | Company | Main Medical Use |
|---|---|---|---|---|
| Olaparib | Olanib | 150 mg | Everest Pharmaceuticals Ltd. | Olaparib-based treatment in applicable cancer indications |
| Olaparib | Olakin | 150 mg | Ziska Pharmaceuticals Ltd. | Olaparib-based treatment in applicable cancer indications |
The Everest product listing identifies Olanib 150 as “Olaparib INN 150 mg.” The Ziska Pharmaceuticals Ltd. official oncology listing identifies Olakin 150 as olaparib.
The presence of the same active ingredient and strength does not by itself establish that two branded products are identical in every formulation or regulatory detail. Product packaging, official product information, and applicable regulatory documentation should be checked.
What Is Olaparib?
Olaparib is a prescription targeted cancer medicine that inhibits PARP enzymes. PARP enzymes participate in the repair of damaged DNA. Cancer cells with defects in other DNA-repair pathways, including certain cancers with BRCA1 or BRCA2 mutations, may be particularly dependent on PARP-mediated repair mechanisms.
By inhibiting PARP, olaparib interferes with DNA repair and can make it more difficult for susceptible cancer cells to survive and reproduce. This mechanism is different from that of conventional cytotoxic chemotherapy and is one reason olaparib is described as a targeted therapy.
Olaparib does not work for every cancer or every patient. Its use depends on the type and stage of cancer, previous treatment, genetic or molecular characteristics of the tumor, treatment history, and the applicable regulatory indication.
What Is Olaparib Used For?
Olaparib has regulatory-approved uses in several cancer settings. The exact indication differs by country and may change as regulatory authorities evaluate new clinical evidence.
According to current European Medicines Agency information, Lynparza containing olaparib is used in specified treatment settings involving:
Ovarian, fallopian-tube, and primary peritoneal cancer
HER2-negative breast cancer associated with germline BRCA1/2 mutations
Metastatic pancreatic adenocarcinoma with specified germline BRCA1/2 mutations
Metastatic castration-resistant prostate cancer in specified molecular and treatment settings
Certain advanced or recurrent endometrial cancers in combination with other medicines
Some uses are maintenance treatments, meaning olaparib is given after an earlier treatment has produced a response or controlled the disease. Other indications involve active treatment of advanced or metastatic cancer.
In the United States, current FDA labeling includes specific ovarian cancer indications, selected breast cancer indications, and olaparib-containing treatment for BRCA-mutated metastatic castration-resistant prostate cancer, including combination treatment with abiraterone and prednisone or prednisolone. Regulatory indications should always be checked against the current prescribing information applicable to the patient’s country.
How Does Olaparib Work?
Olaparib works by blocking PARP enzymes, which help cells repair damaged DNA.
Cancer cells can acquire defects in DNA-repair systems. BRCA1 and BRCA2 are examples of genes involved in important DNA-repair pathways. When certain cancer cells already have significant deficiencies in DNA repair, blocking another repair mechanism through PARP inhibition can create a condition sometimes described as synthetic lethality.
In simple terms, olaparib removes an additional repair pathway that certain cancer cells rely on. The resulting accumulation of DNA damage can interfere with cancer-cell survival.
This targeted mechanism is particularly important in cancers selected according to relevant genetic or molecular characteristics. Genetic testing or an approved companion diagnostic may therefore be required for certain treatment decisions.
How Is Olaparib Generally Taken?
Olaparib is administered orally. Current U.S. prescribing information for Lynparza tablets gives a recommended adult dosage of 300 mg taken twice daily, with or without food, for applicable labeled indications. The 150 mg tablet is therefore one of the tablet strengths used to provide prescribed doses.
The correct dose and treatment schedule must be determined by a qualified healthcare professional.
Patients should:
Take olaparib exactly as prescribed.
Follow the treatment schedule supplied by the oncology team.
Avoid changing the dose independently.
Avoid stopping treatment without professional advice.
Take tablets according to the applicable product instructions.
Tell the healthcare team about all prescription medicines, nonprescription medicines, vitamins and supplements.
Dose adjustments may be necessary in some circumstances, including certain kidney-function limitations or treatment-related adverse reactions.
Important Safety Information
Olaparib can cause clinically important adverse reactions. The FDA prescribing information includes warnings and precautions concerning myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), pneumonitis, and embryo-fetal toxicity, among other safety considerations.
Because olaparib can affect blood cell production, healthcare professionals may monitor blood counts during treatment. Patients should promptly report unexplained bruising or bleeding, persistent fever, unusual infections, marked weakness, shortness of breath, or other concerning symptoms.
Patients should also tell their healthcare professional about pregnancy, plans for pregnancy, and breastfeeding before starting treatment.
Common Side Effects
Possible adverse reactions associated with olaparib include:
Nausea
Fatigue or weakness
Vomiting
Diarrhea
Decreased appetite
Headache
Dizziness
Anemia
Low white blood cell counts
Low platelet counts
Changes in taste
Indigestion or abdominal discomfort
The likelihood and severity of adverse reactions can vary according to the treatment setting, dose, combination therapy, and individual patient factors.
Drug Interactions
Olaparib can interact with other medicines. Some medicines can alter olaparib exposure by affecting enzymes or transport systems involved in its disposition.
Patients should provide their healthcare professional with a complete list of medicines and supplements they use. This includes prescription medicines, over-the-counter products, vitamins, and herbal preparations.
Do not start a new medicine or supplement during olaparib treatment without discussing it with the healthcare team when interaction risk is possible.
Genetic Testing and Treatment Selection
An important feature of olaparib treatment is that some indications depend on specific genetic or molecular characteristics.
BRCA1 and BRCA2 mutations are particularly important in several approved olaparib treatment settings. Other indications may use HRD status or other clinical criteria.
Testing does not mean that every person with a BRCA mutation should receive olaparib. Treatment selection depends on the complete clinical situation, cancer type, treatment history, and applicable regulatory criteria.
Everest Pharmaceuticals Ltd. Product Verification Process
Checking the authenticity of your medicine is an important step before use. If your Everest Pharmaceuticals product includes a QR code and verification code, you can follow these steps:
Scan the QR code
Use your smartphone to scan the QR code printed on the medicine box. It should take you to the designated official product verification page.
Open the Product Box
Carefully open the package and find the verification code printed on the bottle or product packaging.
Enter the Verification Code
Enter the verification code exactly as shown on the official verification page and submit it for authentication.
Check the Verification Result
- Successful verification: The system confirms that the product information matches its records.
- Verification error: The product could not be authenticated through the system. Do not use it until you have confirmed its authenticity through an appropriate official source.
What to Do With a Suspected Counterfeit
If the product appears to be counterfeit, do not use or distribute it. Keep the packaging and purchase information, and contact the relevant pharmaceutical regulatory authority or appropriate official channel for guidance.
Important Safety Advice
Purchase medicines only from licensed pharmacies or authorized suppliers. If you notice unusual packaging, a missing verification code, damaged seals, or an unsuccessful verification result, confirm the product’s authenticity before using it.
Note: A verification result should be interpreted according to the instructions provided by the official Everest Pharmaceuticals verification system.
General Pharmaceuticals Ltd. Product Verification Process
Verifying your medicine before use is an important step in confirming that the product is genuine and comes from an authorized source. General Pharmaceuticals Ltd. provides an electronic verification process to help customers check product authenticity.
How to Verify a General Pharmaceuticals Product
Scan the QR Code: Find the QR code printed on the product box and scan it using your smartphone. The QR code will take you to the official General Pharmaceuticals product verification page.
Open the Verification Page: The QR code directs you to the official General Pharmaceuticals Ltd. E-Verification page, where you can complete the authenticity check.
Complete the Verification: Follow the instructions provided on the official verification page and enter any requested product information or verification code.
Check the Result Carefully: Review the verification result after submitting the required information. A successful verification result can help confirm that the product matches the manufacturer’s records.
What to Do If the Product Cannot Be Verified?
If the verification result indicates that the medicine may be counterfeit, fake, or unauthorized, do not use or distribute the product. Keep the packaging and relevant purchase information and report the suspected counterfeit medicine to the appropriate regulatory authority, such as the Directorate General of Drug Administration (DGDA), World.
Medical Disclaimer
Olaparib is a prescription anticancer medicine and should be used only under appropriate professional medical supervision.
The information on Olaparib150mg.com is intended for general educational purposes. It does not replace a physician’s assessment, diagnosis, prescription, treatment plan, or official prescribing information.
Patients should not start olaparib, stop treatment, change the dose, or alter the treatment schedule solely based on information published online.
Regulatory indications, product information, and treatment recommendations can vary between countries. Always consult the current official product information and a qualified healthcare professional.
Latest News
FAQs
Olaparib may be prescribed to selected patients with specific cancers when their disease and clinical characteristics meet the requirements of an approved treatment indication. Eligibility can depend on cancer type, genetic or biomarker findings, previous treatment, and other clinical factors.
A PARP inhibitor is a medicine that blocks PARP proteins involved in repairing damaged DNA. Olaparib belongs to this class. Blocking these repair processes can make it harder for certain cancer cells with existing DNA-repair weaknesses to survive.
Homologous recombination repair is a cellular process used to accurately repair certain types of DNA damage. Genes such as BRCA1 and BRCA2 are involved in this pathway. Defects in this repair system can be relevant to treatment decisions involving olaparib.
Genetic or tumor testing may help determine whether a patient's cancer has characteristics relevant to an approved olaparib indication. Depending on the cancer, testing may include BRCA1 or BRCA2 alterations or other DNA-repair-related biomarkers. Your healthcare team will determine which tests are appropriate.
Yes. In certain approved treatment settings, olaparib can be used as maintenance therapy after a patient has responded to or has stable disease following previous treatment. The exact eligibility requirements depend on the cancer type and applicable regulatory approval.
Before starting treatment, make sure your healthcare team knows about your cancer diagnosis, previous treatments, current medicines, supplements, kidney or liver problems, pregnancy status, and relevant genetic or biomarker test results. Your doctor may also arrange baseline blood tests or other assessments.
Olaparib can cause effects such as dizziness, weakness, or tiredness in some patients. If you experience symptoms that affect alertness, concentration, balance, or coordination, avoid driving or operating machinery until you know how the medicine affects you and have discussed any concerns with your healthcare professional.
Yes. Olaparib can cause changes in blood-cell counts, including anemia and reductions in white blood cells, neutrophils, or platelets. Regular blood tests may therefore be recommended during treatment to identify clinically important changes.
Do not assume that tablets are safe to use if their appearance is unexpectedly different. Check the product name, strength, packaging, batch information, and expiry date, and ask a pharmacist or healthcare professional to confirm the medicine before taking it if you have concerns.
Check that the packaging identifies the correct product, active ingredient, strength, manufacturer, batch or lot number, and expiry date. For products that provide an official authentication system, follow the manufacturer's verification instructions. If anything appears suspicious or inconsistent, consult a pharmacist or the relevant manufacturer before using the medicine.